Loading patent…
AssigneeThe Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Hol
InventorsMatthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'neill
Estimating the term…
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.
A method of treating degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation comprising administering inflammatory mediators, components, or substrates of the NLRP3-inflammasome to a subject in need thereof.
(canceled)
A recombinant viral gene delivery vector which directs the expression of IL-18 in a form suitable for the treatment of choroidal neo-vascularisation.
(canceled)
(canceled)
(canceled)
A method for treating a subject affected by or at risk of developing a disease involving drusen and anaphylatoxin-induced choroidal neo-vascularisation, the method comprising:
Dependencies are inferred from the claim text.